A Comprehensive Monograph on Tetracaine (Amethocaine): Pharmacology, Clinical Utility, and Safety Profile

Section 1: Identification and Historical Context

This section establishes the fundamental identity of Tetracaine, detailing its nomenclature, classification, and unique identifiers. It further places the drug within its historical and regulatory context, from its synthesis in the early 20th century to its modern status as an essential medicine.

1.1 Nomenclature and Chemical Classification

The local anesthetic Tetracaine is recognized globally by several names. Its United States Adopted Name (USAN) is Tetracaine, while its International Nonproprietary Name (INN) is Amethocaine.[1] Historically and commercially, it has also been known by various trade names, including Pontocaine, Dicaine, and Ametop.[1]

Chemically, its systematic International Union of Pure and Applied Chemistry (IUPAC) name is 2-(dimethylamino)ethyl 4-(butylamino)benzoate.[2] Tetracaine is classified as a local anesthetic belonging to the amino-ester class, a categorization critical to understanding its metabolic pathway, duration of action, and potential for allergic reactions.[1] It is specifically a benzoate ester, formed through the chemical combination of a lipophilic aromatic acid (4-N-butylbenzoic acid) and a hydrophilic amino alcohol (2-(dimethylamino)ethanol).[2] This amphipathic structure, possessing both fat-soluble and water-soluble components, is the archetypal design for local anesthetic agents and is fundamental to its ability to interact with and block neuronal membranes.

1.2 Key Identification Codes

For unambiguous identification in global databases, regulatory filings, and scientific literature, Tetracaine and its hydrochloride salt are assigned a comprehensive set of unique identifiers. These codes are essential for accurate cross-referencing and data retrieval.

• DrugBank ID: DB09085 [1]
• CAS (Chemical Abstracts Service) Number: 94-24-6 (for the free base); 136-47-0 (for the monohydrochloride salt) [1]
• PubChem Compound ID (CID): 5411 [1]
• UNII (Unique Ingredient Identifier): 0619F35CGV (for the free base); 5NF5D4OPCI (for the hydrochloride salt) [1]
• Anatomical Therapeutic Chemical (ATC) Codes: D04AB06 (Topical anesthetics), N01BA03 (Anesthetics, local; Esters of aminobenzoic acid), S01HA03 (Ophthalmic anesthetics), C05AD02 (Topical products for hemorrhoids and anal fissures) [10]
• Other Database Identifiers:
• ChEBI: CHEBI:9468 [1]
• ChEMBL: ChEMBL698 [1]
• KEGG: D00551 (base); D00741 (HCl salt) [1]
• EPA CompTox Dashboard: DTXSID1043883 [1]

1.3 Historical Milestones: Discovery and Introduction to Clinical Practice

The development of Tetracaine is rooted in the period of intense synthetic pharmaceutical innovation of the early 20th century. It was first synthesized in Germany in 1928 by the chemist Otto Eisleb, a researcher at the formidable chemical conglomerate IG Farben.[4] Eisleb's work was significant; he would later, in 1939, create meperidine (Demerol), the first fully synthetic opioid, underscoring his pivotal role in the development of modern analgesics and anesthetics.[4]

Following its discovery, Tetracaine was patented in 1930 and was introduced into widespread medical use in 1941.[1] Its entry into the American market was facilitated by the Winthrop Chemical Company of New York, which marketed the drug under the well-known brand name Pontocaine.[4] This introduction was the result of a complex and multifaceted business relationship established in 1923 between Winthrop's parent company, Sterling Products, and IG Farben, which effectively provided the German chemical giant with access to the U.S. market.[4]

Tetracaine's regulatory history in the United States is particularly noteworthy. Its use in ophthalmology predates the landmark 1962 Kefauver-Harris Amendments to the Federal Food, Drug, and Cosmetic Act, which for the first time required drug manufacturers to provide proof of effectiveness in addition to safety. Because of this, ophthalmic Tetracaine was marketed for over 45 years with the status of an "unapproved drug".[11] This regulatory anomaly was resolved when Alcon Research, Ltd. submitted a 505(b)(2) New Drug Application (NDA 208-135) to the U.S. Food and Drug Administration (FDA). This specific regulatory pathway allows for the use of published literature and prior FDA findings in lieu of conducting entirely new clinical trials. Based on the extensive historical evidence of its safety and efficacy, the NDA was approved, bringing this legacy drug into full regulatory compliance.[11] This process highlights a pragmatic mechanism for regularizing well-established, pre-amendment drugs and affirms the value of historical clinical data in modern regulatory science.

1.4 Position as an Essential Medicine

Reflecting its long-standing clinical utility, proven efficacy, and relative affordability, Tetracaine is included on the World Health Organization's (WHO) List of Essential Medicines.[1] This designation signifies that it is considered a critical medication required to meet the minimum needs of a basic healthcare system, ensuring its continued importance in providing accessible and effective anesthesia worldwide.

Section 2: Physicochemical Characteristics

The pharmacological behavior, clinical efficacy, formulation strategies, and safety profile of Tetracaine are fundamentally dictated by its chemical and physical properties. A detailed understanding of these characteristics is essential for its appropriate and safe use.

2.1 Chemical Structure and Formula

Tetracaine is a small molecule with the molecular formula C15​H24​N2​O2​.[1] As a classic amino-ester local anesthetic, its structure is amphipathic, comprising three key components:

1. A lipophilic (fat-soluble) aromatic ring, derived from p-butylaminobenzoic acid, which facilitates penetration of the lipid-rich nerve membrane.
2. An intermediate ester linkage (–COO–), which is the site of metabolic hydrolysis and a key determinant of its duration of action and allergic potential.
3. A hydrophilic (water-soluble) tertiary amine group (a dimethylaminoethyl moiety), which exists in both charged (ionized) and uncharged (non-ionized) forms at physiological pH, enabling both membrane passage and receptor binding.[2]

For computational chemistry and database searching, its structure is unambiguously represented by identifiers such as its SMILES (Simplified Molecular Input Line Entry System) string, CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C, and its InChIKey, GKCBAIGFKIBETG-UHFFFAOYSA-N.[1]

2.2 Molecular Properties

Several key molecular properties govern Tetracaine's pharmacodynamic and pharmacokinetic profile:

• Molar Mass: The free base has a molar mass of 264.369 g·mol⁻¹.[1] The clinically used hydrochloride salt has a molar mass of 300.82 g·mol⁻¹.[9]
• pKa: The pKa of Tetracaine is 8.46 at room temperature (25°C).[6] The pKa is the pH at which 50% of the drug is in its ionized (cationic, active) form and 50% is in its non-ionized (uncharged, membrane-penetrating) form. Since this is higher than physiological pH (≈7.4), at body temperature, a larger fraction of the drug exists in the ionized state, yet a sufficient amount of the non-ionized form is present to allow for rapid diffusion across nerve membranes.
• Lipid Solubility: Tetracaine possesses a high lipid solubility, with a relative value of 80.[6] This property is directly responsible for its high potency, as it allows the molecule to readily partition into and traverse the lipid bilayer of the nerve axon.
• Protein Binding: The drug exhibits moderate binding to plasma proteins, cited at approximately 75%.[6] This binding acts as a temporary reservoir for the drug, contributing to its prolonged duration of action by slowing its clearance from the site of action.

The relationship between these properties illustrates a fundamental principle in local anesthetic pharmacology. The high lipid solubility that confers high potency, combined with the moderate protein binding and slow metabolism characteristic of its ester structure, results in a potent and long-acting but also potentially more systemically toxic agent. This balance between efficacy and risk is a central theme in the clinical profile of Tetracaine.

2.3 Physical Properties and Stability

• Appearance: In its pure form, Tetracaine is a white to off-white, crystalline, odorless powder.[13]
• Solubility: The free base is soluble in organic solvents like dimethyl sulfoxide (DMSO) and methanol.[15] The hydrochloride salt is readily soluble in water, physiologic saline, and dextrose solutions, which is essential for its formulation as an injectable or ophthalmic product.[17]
• Melting and Boiling Points: The melting point of the base is reported as 43°C [16], and its boiling point is approximately 389.4°C at standard pressure.[15]
• Stability and Storage: Tetracaine solutions are susceptible to slow hydrolysis, particularly when exposed to changes in pH or temperature. This degradation can lead to the precipitation of one of its metabolites, p-butylaminobenzoic acid, which appears as visible crystals in the solution. For this reason, any solutions that are cloudy, discolored, or contain precipitate must be discarded.[18] To ensure stability, the drug should be protected from light and moisture.[15] Recommended storage conditions vary by formulation: ophthalmic solutions are typically stored at controlled room temperature (15°C to 25°C or 59°F to 77°F) [13], whereas the bulk powder is stored frozen at -20°C for long-term stability.[5]

2.4 Hazard Classification

According to the Globally Harmonized System of Classification and Labelling of Chemicals (GHS), Tetracaine is classified as a hazardous substance. It is assigned the signal word "Danger" and is associated with several hazard statements, including H301 (Toxic if swallowed), H317 (May cause an allergic skin reaction), and H351 (Suspected of causing cancer).[15] For transportation, it is classified as a Dangerous Good under UN 2811 (Toxic solid, organic, n.o.s.).[15]

The hazard statement H351, "Suspected of causing cancer," warrants careful interpretation, as it appears to conflict with regulatory assessments. This classification, often found on chemical supplier safety data sheets, is typically based on structural alerts (e.g., the presence of an aromatic amine group) or limited in vitro data. It reflects a precautionary principle from a chemical hazard perspective. In contrast, formal drug safety evaluations by regulatory bodies like the FDA require extensive, long-term animal studies to make a definitive statement on carcinogenicity. The FDA's pharmacology review for NDA 208135 explicitly states that "Long-term animal studies have not been conducted to evaluate the carcinogenic potential of tetracaine hydrochloride" and that studies to assess its genotoxicity have not been reported in the published literature.[13] This discrepancy does not represent a factual contradiction but rather highlights the different evidentiary standards of chemical hazard classification versus formal drug toxicology assessment. Thus, while a suspicion of risk exists based on its chemical structure, a definitive risk has not been established through rigorous, regulatory-standard testing.

---

Table 2.1: Summary of Physicochemical Properties of Tetracaine

Property	Value	Source(s)
Chemical Classification	Amino-ester local anesthetic	6
Molecular Formula	C15​H24​N2​O2​	1
Molar Mass (Base)	264.369 g·mol⁻¹	1
Molar Mass (HCl Salt)	300.82 g·mol⁻¹	9
Appearance	White to off-white crystalline powder	13
pKa (at 25°C)	8.46	6
Lipid Solubility (Relative)	High (80)	6
Plasma Protein Binding	~75%	6
Melting Point	43 °C / 109.4 °F	16
Boiling Point	389.4 ± 27.0 °C at 760 mmHg	15
Solubility (HCl Salt)	Readily soluble in water, dextrose	17
Storage (Ophthalmic)	15°C to 25°C (59°F to 77°F)	13
Storage (Powder, Long-term)	-20°C	5
GHS Hazard Signal Word	Danger	15

---

Section 3: Comprehensive Pharmacology

The clinical utility of Tetracaine stems from a well-defined set of pharmacological actions. This section provides a multi-layered analysis of its mechanism of action at the molecular level, its pharmacodynamic effects on the nervous system, and its pharmacokinetic profile, which describes its journey through the body.

3.1 Mechanism of Action

While Tetracaine is known clinically for a single purpose—producing anesthesia—its interactions at the molecular level are more diverse, giving it a dual identity as both a clinical tool and a research probe.

3.1.1 Primary Action: Voltage-Gated Sodium Channel Blockade

The principal mechanism by which Tetracaine produces local anesthesia is the reversible blockade of voltage-gated sodium (Na+) channels located within the membranes of nerve axons.[6] This process occurs in several distinct steps:

1. Membrane Penetration: Following administration, the uncharged, non-ionized (lipophilic) form of the Tetracaine molecule diffuses from the extracellular space across the lipid-rich axonal membrane into the axoplasm (the cytoplasm of the nerve cell).[6]
2. Ionization: Once inside the relatively acidic environment of the axoplasm, the drug re-equilibrates, and a portion becomes protonated, converting to its positively charged, ionized (cationic) form.[6]
3. Receptor Binding: This ionized form of Tetracaine then binds to a specific receptor site located on the intracellular side of the sodium channel's α-subunit.[6]
4. Channel Blockade: This binding event stabilizes the sodium channel in its inactivated state, physically obstructing the channel pore and preventing the influx of sodium ions that is necessary for membrane depolarization.[23]
5. Inhibition of Action Potential: By preventing depolarization from reaching the threshold potential, Tetracaine blocks both the initiation and the conduction of action potentials along the nerve fiber. For nerve conduction to be fully impaired, this blockade must occur at a minimum of three successive nodes of Ranvier.[6] The result is a cessation of sensory signal transmission from the periphery to the central nervous system, which is perceived as numbness or anesthesia.

Furthermore, Tetracaine exhibits "use-dependent" blockade, meaning it binds more readily and effectively to sodium channels that are in the open or activated state—that is, channels on nerves that are actively firing.[6] This property makes it particularly effective at blocking pain signals in actively stimulated nerve pathways.

3.1.2 Secondary and Research-Relevant Actions

Beyond its primary anesthetic function, Tetracaine has well-documented effects on other ion channels, making it a valuable tool in basic science research:

• Ryanodine Receptor Modulation: In biomedical research, particularly in muscle physiology and studies of intracellular signaling, Tetracaine is widely used as a modulator of calcium (Ca2+) release channels, specifically ryanodine receptors (RyR1 in skeletal muscle and RyR2 in cardiac muscle).[1] It acts as an allosteric blocker of these channels, which control the release of calcium from intracellular stores like the sarcoplasmic reticulum. At low concentrations, Tetracaine causes a partial inhibition of spontaneous Ca2+ release events (known as "calcium sparks"), while at high concentrations, it blocks Ca2+ release completely.[1] This specific action allows researchers to probe the mechanisms of excitation-contraction coupling and other calcium-dependent cellular processes.
• Nicotinic Acetylcholine Receptor Blockade: Research has also demonstrated that Tetracaine can reversibly block nicotinic acetylcholine (nACh) receptors, another class of ligand-gated ion channels.[15]

This dual identity is important for a complete understanding of the drug. While its Na+ channel blockade is the basis of its clinical use, its effects on RyR channels are central to its role as a laboratory reagent. The concentrations and physiological contexts for these two actions differ, but both are integral to the drug's overall pharmacological profile.

3.2 Pharmacodynamics

Pharmacodynamics describes the effects of the drug on the body. For Tetracaine, these are defined by its potency, onset, and duration of action.

• Potency: Tetracaine is a highly potent local anesthetic, considered among the most potent of all agents used clinically.[5] Its potency is a direct consequence of its high lipid solubility, which allows it to efficiently penetrate nerve membranes and reach its intracellular target.[6] In comparative terms, it is approximately 10 times more potent than the prototypical ester anesthetic, procaine.[24]
• Onset of Action: The onset of anesthesia is generally rapid. When administered as ophthalmic drops, the numbing effect begins within 10 to 30 seconds.[1] For spinal anesthesia, where the drug must diffuse within the cerebrospinal fluid, the onset is slightly slower, typically occurring within 5 to 10 minutes.[27]
• Duration of Action: Tetracaine provides a prolonged duration of anesthesia. In ophthalmic procedures, a single application lasts for 10 to 20 minutes, but this can be readily extended with repeated doses.[1] When used for spinal anesthesia, its effects are much longer, providing surgical anesthesia for up to 2 to 3 hours.[6] This long duration is attributable to a combination of its moderate plasma protein binding (≈75%) and its relatively slow rate of metabolic breakdown.[6]

3.3 Pharmacokinetics

Pharmacokinetics describes the movement of the drug through the body—its absorption, distribution, metabolism, and excretion (ADME).

3.3.1 Absorption

Systemic absorption of Tetracaine from its site of administration is highly variable and depends critically on the vascularity of the tissue. The rate of absorption from fastest to slowest follows a predictable pattern: intravenous (direct administration) > intercostal nerve block > caudal > epidural > brachial plexus block > subcutaneous injection.[6] When applied topically to the skin, systemic absorption is directly proportional to the surface area and duration of application.[8] Absorption from the eye is generally low; plasma levels following ophthalmic administration are often below the limit of detection (<0.9 ng/mL), largely because the drug is rapidly hydrolyzed locally and in the plasma before significant amounts can enter systemic circulation.[8]

3.3.2 Distribution

Once absorbed, the distribution of Tetracaine is influenced by its physicochemical properties. Due to its rapid breakdown in the plasma, classic pharmacokinetic parameters like the volume of distribution have been difficult to determine precisely in human studies.[8] However, its moderate protein binding of approximately 75% helps to localize the drug and prolong its action.[6] An interesting characteristic is its high affinity for melanin, the pigment found in the iris and other tissues. This binding can lead to a longer duration of anesthetic effect in individuals with darkly pigmented eyes compared to those with lightly pigmented eyes.[29]

3.3.3 Metabolism

As an amino-ester anesthetic, Tetracaine is metabolized primarily via hydrolysis by the enzyme plasma cholinesterase (also known as pseudocholinesterase or butyrylcholinesterase), which is synthesized in the liver and circulates in the blood.[6] This metabolic pathway is a key feature of the ester class of anesthetics. The ester bond in the Tetracaine molecule is cleaved, breaking it down into two primary metabolites: para-aminobenzoic acid (PABA) and diethylaminoethanol.[6] The pharmacological activity of these metabolites is considered unspecified or inactive.[8]

Crucially, among the common ester anesthetics (chloroprocaine, procaine, tetracaine), Tetracaine has the slowest rate of hydrolysis.[24] This slow metabolism is a double-edged sword: it is a major contributor to the drug's long duration of action, but it is also the primary reason for its higher potential for systemic toxicity compared to more rapidly metabolized esters.

The metabolic pathway of Tetracaine is the nexus of several major clinical risks. First, the slow rate of hydrolysis directly increases the risk of the drug accumulating to toxic levels in the plasma. Second, the PABA metabolite is a known antigen and is responsible for the allergic reactions associated with ester anesthetics. Third, PABA is structurally similar to a substrate required by bacteria, and its presence can antagonize the action of sulfonamide antibiotics. Therefore, this single metabolic process is the origin of three distinct clinical concerns: systemic toxicity, allergy, and a significant drug-drug interaction.

3.3.4 Excretion

Following metabolism, the water-soluble metabolites, principally PABA, are eliminated from the body via renal excretion in the urine.[28] Only a minimal amount of the parent Tetracaine drug is excreted unchanged in the urine.[6]

Section 4: Clinical Applications and Administration

Tetracaine's potent anesthetic properties have secured its place in several distinct clinical domains. Its utility is not defined by the active molecule alone, but by the specific formulation that tailors its properties for use in vastly different physiological environments, from the delicate surface of the cornea to the sterile subarachnoid space of the spinal canal.

4.1 Ophthalmic Anesthesia

The most common contemporary use of Tetracaine is as a topical anesthetic in ophthalmology.[6] It is indicated for procedures that require rapid and short-acting surface anesthesia of the eye.[13]

• Indications: Common applications include preparing the eye for tonometry (measurement of intraocular pressure), removal of corneal foreign bodies or sutures, and providing anesthesia for more extensive surgeries like cataract extraction.[1]
• Formulation: It is typically supplied as a 0.5% sterile, buffered ophthalmic solution.[13]
• Dosing: The dosing regimen is adjusted based on the required duration of anesthesia [6]:
• Brief Procedures (e.g., tonometry): 1 to 2 drops are instilled into the affected eye(s) immediately prior to the procedure.
• Minor Surgical Procedures (e.g., foreign body removal): 1 to 2 drops are instilled every 5 to 10 minutes, for a total of 1 to 3 doses.
• Prolonged Anesthesia (e.g., cataract surgery): 1 to 2 drops are instilled every 5 to 10 minutes, for a total of 3 to 5 doses to maintain the anesthetic effect.

4.2 Topical and Dermal Anesthesia

Tetracaine is also used as a topical anesthetic on the skin and mucous membranes.

• Indications: It is applied to the skin to relieve the pain and itching associated with minor sunburns, rashes, or other mild skin irritations.[3] It is also used to numb the skin before minor medical procedures, such as the insertion of an intravenous (IV) line, an application that has been particularly studied in children to reduce procedural pain.[1]
• Formulations: It is available as a stand-alone product in the form of a gel, solution, or cream.[3] More commonly, it is a component in combination products designed to enhance efficacy. Examples include:
• Lidocaine/Tetracaine: Marketed as a topical patch (Synera) or cream (Pliaglis), this combination creates a eutectic-like mixture that enhances dermal penetration and provides a broad spectrum of anesthesia.[8]
• Benzocaine/Butamben/Tetracaine: A combination spray or gel (Cetacaine) used for anesthesia of mucous membranes, particularly in dental and throat procedures.[10]
• TAC: Tetracaine is the "T" in TAC, a historically significant topical solution containing Tetracaine, Adrenaline (epinephrine), and Cocaine. TAC is used in emergency departments and ear, nose, and throat (ENT) surgery for rapid, profound surface numbing, especially for laceration repair on the face and scalp in children.[1]
• Administration: When used topically, a thin film of the product is applied to the affected area. It is critical that it not be applied to large areas of skin, deep puncture wounds, or broken/inflamed skin, as this can lead to excessive systemic absorption and toxicity.[3]

An important and concerning finding is the illicit use of Tetracaine as an adulterant in unregulated products marketed as male sexual function enhancers.[39] It is presumably added to induce local numbness and thereby delay ejaculation. This practice represents a significant public health risk, as consumers are unknowingly exposed to a potent, prescription-only anesthetic with a substantial side effect profile, including the potential for systemic toxicity, allergic reactions, and unintentional transfer to a sexual partner. This highlights a forensic and public safety dimension to the drug's profile beyond its controlled medical use.

4.3 Spinal Anesthesia

Tetracaine is a well-established agent for producing spinal (intrathecal) anesthesia, particularly for procedures requiring a longer duration of action.[6] It is classified as a long-acting spinal anesthetic, with effects lasting 2 to 3 hours.[27]

• Formulations and Preparation: For spinal use, Tetracaine is available as a 1% solution or as a 20 mg lyophilized powder in an ampule (a form referred to as "Niphanoid" crystals) that is reconstituted before use.[4] The key to controlling the spread and level of anesthesia within the spinal canal is the manipulation of the solution's baricity—its density relative to cerebrospinal fluid (CSF).
• Hyperbaric (heavier than CSF): This is the most commonly used form. The solution is made heavier than CSF by mixing the 1% Tetracaine solution with an equal volume of 10% dextrose injection or by dissolving the powder directly in a 10% dextrose solution.[18] When injected, a hyperbaric solution will travel with gravity, settling in the most dependent part of the spinal canal based on patient positioning. This is useful for procedures like a "saddle block" for vaginal delivery.
• Isobaric (same density as CSF): The commercially available 1% solution is isobaric (specific gravity ≈1.006-1.007).[18] An isobaric solution tends to remain at the level of injection, providing a more localized block.
• Hypobaric (lighter than CSF): A solution lighter than CSF can be prepared by dissolving the Tetracaine powder in preservative-free sterile water.[18] A hypobaric solution will rise against gravity, which is useful for anesthetizing structures in the non-dependent part of the spinal canal.
• Dosing: The dose is carefully titrated based on the desired dermatomal level of anesthesia [17]:
• Perineal anesthesia (saddle block): 2 mg to 5 mg.
• Anesthesia of the lower extremities: 10 mg.
• Anesthesia up to the costal margin (mid-abdomen): 15 mg to 20 mg. Doses exceeding 15 mg are rarely necessary and should be used with caution.[17]
• Adjuvants: Epinephrine (0.1–0.2 mg) is often added to the Tetracaine solution. As a vasoconstrictor, it reduces blood flow at the site of action, which decreases the rate of systemic absorption, thereby prolonging the duration of the spinal block and reducing the risk of systemic toxicity.[27]

4.4 Formulations and Brand Names

The same active ingredient, Tetracaine, is marketed under a wide array of brand names and in numerous formulations, each tailored to a specific clinical niche.

---

Table 4.1: Commercial Formulations and Brand Names of Tetracaine

Brand Name(s)	Manufacturer(s)	Formulation	Primary Indication(s)	Source(s)
Pontocaine HCl, Niphanoid	Hospira	Injectable solution (1%), Powder for injection (20 mg)	Spinal Anesthesia	10
Pontocaine with Dextrose	Sanofi, Hospira	Injectable solution (0.2% or 0.3% in 6% Dextrose)	Spinal Anesthesia (Hyperbaric)	18
Altacaine, Tetcaine, TetraVisc, Pontocaine Ophthalmic, Opticaine, AK-T-Caine	Various	Ophthalmic solution (0.5%)	Ophthalmic Anesthesia	10
Tetracaine HCl Ophthalmic Solution 0.5% STERI-UNIT®	Alcon	Ophthalmic solution (0.5%)	Ophthalmic Anesthesia	34
Pontocaine, Viractin, Dermocaine	Various	Topical solution, cream, gel	Topical Anesthesia (minor skin irritation)	3
Synera, Pliaglis, S-Caine Peel	ZARS, Inc., Galderma	Topical patch or cream (Lidocaine/Tetracaine combination)	Dermal Anesthesia (for procedures)	8
Kovanaze	St. Renatus LLC	Nasal spray (Oxymetazoline/Tetracaine combination)	Dental Anesthesia	10
Cetacaine	Cetylite	Topical spray, liquid, gel (Benzocaine/Butamben/Tetracaine)	Mucosal Anesthesia (mouth/throat)	10
TAC	Compounded	Topical solution (Tetracaine/Adrenaline/Cocaine)	Topical Anesthesia (laceration repair)	1

---

Section 5: Safety Profile, Toxicology, and Risk Management

While an effective anesthetic, Tetracaine is a potent drug with a significant potential for local and systemic toxicity. A thorough understanding of its adverse effects, contraindications, and management of overdose is paramount for its safe clinical use.

5.1 Adverse Effects

Adverse effects can be categorized by the site of application and the potential for systemic toxicity.

• Local and Topical Reactions: The most frequently reported side effects are transient and confined to the site of application. These include a sensation of burning, stinging, itching, skin redness (erythema), and tenderness.[1] When used in combination patches (e.g., with lidocaine), localized erythema, skin discoloration, and edema are common.[8]
• Ocular Toxicity (Anesthetic Abuse Keratopathy): This is the most serious local complication. While a single application in a clinical setting is safe, prolonged use or abuse of ophthalmic Tetracaine is severely toxic to the cornea. It directly inhibits the migration and division of corneal epithelial cells, leading to a cascade of damage.[13] This can manifest as persistent epithelial defects, stromal edema, characteristic ring-shaped stromal infiltrates, and ultimately may progress to permanent corneal opacification, ulceration, perforation, and vision loss.[1] This creates a dangerous paradox: the drug's profound pain relief can incentivize patient abuse, which in turn causes more damage and pain, leading to a vicious cycle of further abuse. For this reason, patients must be strictly warned not to touch, rub, or otherwise injure the eye while it is numb.[32]
• Central Nervous System (CNS) Toxicity: This is a primary concern if significant systemic absorption occurs. The symptoms typically progress through a biphasic pattern.
• Initial Symptoms: Early signs include numbness around the mouth (circumoral numbness) and of the tongue, a metallic taste, tinnitus (ringing in the ears), blurred vision, lightheadedness, and dizziness.[6]
• Excitatory Phase: As plasma concentrations rise, inhibitory pathways in the CNS are blocked first, leading to a state of excitation characterized by nervousness, restlessness, muscle twitching, tremors, and potentially generalized seizures (convulsions).[6]
• Depressive Phase: If toxicity progresses, the excitatory phase is followed by profound CNS depression, manifesting as drowsiness, confusion, loss of consciousness, coma, and ultimately, respiratory arrest.[6]
• Cardiovascular System (CVS) Toxicity: High systemic levels of Tetracaine are directly toxic to the myocardium. It exerts a dose-dependent decrease in cardiac contractility and can cause significant electrophysiological changes.[6] This may manifest as hypotension (due to both myocardial depression and vasodilation), bradycardia, and arrhythmias. Electrocardiogram (ECG) changes can include a prolongation of the PR and QRS intervals. In severe cases, toxicity can progress to profound bradycardia, asystole, and complete cardiovascular collapse.[6]
• Allergic Reactions: As an ester-type anesthetic, Tetracaine carries a risk of true allergic reactions. These are typically mediated by its metabolite, para-aminobenzoic acid (PABA), which can act as an antigen.[24] Reactions can range from localized cutaneous lesions like urticaria (hives) and edema to, in rare instances, severe, life-threatening systemic anaphylaxis.[1]

5.2 Contraindications and High-Risk Populations

• Absolute Contraindications:
• Known hypersensitivity to Tetracaine, any other ester-type local anesthetic (e.g., procaine, benzocaine), or to its metabolite, PABA.[13]
• For ophthalmic formulations, it is strictly contraindicated for injection or intracameral use (injection into the anterior chamber of the eye), as this can cause severe damage to the corneal endothelium.[13]
• Precautions and High-Risk Populations:
• Pseudocholinesterase Deficiency: Patients with a genetic deficiency or reduced levels of plasma cholinesterase will metabolize Tetracaine much more slowly, placing them at a significantly higher risk for developing systemic toxicity even with normal doses. Caution is essential in this population.[3]
• Cardiovascular Disease: Patients with pre-existing heart disease may have a reduced tolerance for the cardiodepressant effects of the drug.[31]
• Hepatic Disease: Since plasma cholinesterase is produced in the liver, severe liver disease could potentially impair metabolism and increase toxicity risk.[6]
• Application Site Integrity: The risk of systemic toxicity is greatly increased if the drug is applied over large surface areas, or to skin that is broken, inflamed, or severely irritated, as these conditions enhance systemic absorption.[3]

5.3 Significant Drug Interactions

• Methemoglobinemia-Inducing Agents: Tetracaine can contribute to the development of methemoglobinemia, a rare but serious condition where hemoglobin is oxidized and cannot carry oxygen. This risk is additively increased when Tetracaine is co-administered with a wide range of other drugs known to cause methemoglobinemia. This creates a hidden network of risk, as many of these interacting drugs are common. Examples include:
• Analgesics (acetaminophen)
• Nitrates (nitroglycerin, isosorbide dinitrate/mononitrate)
• Other local anesthetics (benzocaine, lidocaine, prilocaine)
• Antibiotics (dapsone, nitrofurantoin, sulfonamides)
• Antineoplastics (cyclophosphamide, flutamide)
• Antimalarials (chloroquine, primaquine) This extensive list underscores the critical importance of obtaining a thorough medication history before administering Tetracaine.8
• Sulfonamides: The PABA metabolite of Tetracaine can competitively inhibit the action of sulfonamide antibiotics, rendering them less effective. Therefore, Tetracaine should not be used in patients actively being treated with these agents.[18]
• CNS Depressants: The sedative effects of Tetracaine can be potentiated by co-administration with other CNS depressants, such as benzodiazepines, opioids, barbiturates, and general anesthetics, increasing the risk of drowsiness and respiratory depression.[8]
• Hyaluronidase: This enzyme is sometimes added to local anesthetic solutions to speed their spread and onset of action. However, it also increases the rate of systemic absorption, which shortens the duration of the anesthetic block and increases the risk of systemic toxic reactions.[31]

5.4 Overdose and Local Anesthetic Systemic Toxicity (LAST)

An overdose of Tetracaine can be fatal and constitutes a medical emergency known as Local Anesthetic Systemic Toxicity (LAST).

• Causes and Risk Factors: Overdose typically results from excessive systemic absorption, which can be caused by administering too large a dose, accidental intravascular injection, or applying the topical form to a large surface area, to broken skin, or with the application of heat or an occlusive dressing.[35]
• Symptoms: The symptoms of LAST are a severe manifestation of the CNS and cardiovascular adverse effects described above, including profound cardiac arrhythmias, intractable seizures, coma, and cardiorespiratory arrest.[6]
• Management: The management of LAST requires immediate and aggressive intervention.

1. Stop the Injection and Call for Help: The first step is to cease administration of the anesthetic and summon assistance, as management is resource-intensive.[44]
2. Airway Management: The immediate priority is to manage the patient's airway and provide 100% oxygen to prevent hypoxia and hypercarbia. Acidosis potentiates LA toxicity, so adequate ventilation is crucial. Endotracheal intubation may be necessary.[6]
3. Seizure Control: Seizures should be suppressed promptly. Benzodiazepines (e.g., midazolam, diazepam) are the first-line treatment as they have minimal cardiodepressant effects. Small doses of propofol or thiopental can be used, but with extreme caution as they can worsen hypotension and cardiac depression.[6]
4. Lipid Emulsion Therapy ("Lipid Rescue"): For any signs of serious cardiac toxicity, the definitive treatment is the immediate intravenous administration of a 20% lipid emulsion. This therapy is thought to work by creating a "lipid sink" in the plasma that sequesters the lipophilic anesthetic molecules, drawing them away from their sites of action in the heart and brain.[6]

5.5 Detailed Toxicology

Toxicological data, primarily from animal studies and safety data sheets, provide quantitative measures of acute toxicity.

• Acute Toxicity (LD₅₀): The LD₅₀ is the dose lethal to 50% of a test population.
• Oral, Rat: 160 mg/kg [46]
• Oral, Mouse: 300 mg/kg [19]
• Intraperitoneal, Mouse: 20 mg/kg [19]
• Intraperitoneal, Rat: 33 mg/kg [19]
• Subcutaneous, Mouse: 41.5 mg/kg (reported as 41,500 µg/kg) [19]
• Carcinogenicity and Mutagenicity: As detailed in Section 2.4, there is a discrepancy between chemical hazard classifications, which list it as "Suspected of causing cancer" (H351), and formal regulatory assessments, which note a lack of definitive long-term studies.[14]
• Irritation: It is classified as a serious eye irritant and a skin irritant.[16]

Section 6: Contemporary Research and Clinical Evidence

While Tetracaine is a long-established drug, its clinical applications and our understanding of its risk-benefit profile continue to evolve. This evolution is driven by ongoing biomedical research and modern, evidence-based clinical trials.

6.1 Role in Biomedical Research

As established previously, Tetracaine's utility extends beyond the clinic into the basic science laboratory. Its specific and potent action as an allosteric blocker of ryanodine receptor (Ca2+) channels has made it an indispensable pharmacological tool. Researchers in fields such as muscle physiology, cardiology, and neuroscience routinely use Tetracaine to investigate the mechanisms of excitation-contraction coupling, intracellular calcium signaling, and other fundamental cellular processes that are dependent on controlled calcium release from internal stores.[1]

6.2 Clinical Trials in Pain Management and Anesthesia

A review of the clinical trials registry (ClinicalTrials.gov) shows that Tetracaine remains an active subject of investigation, both as a single agent and, increasingly, as a component of combination therapies designed to optimize its anesthetic properties while mitigating risk.[37]

A key trend in modern pharmacology is the development of synergistic formulations. For Tetracaine, this has led to several innovative products. The combination with another local anesthetic, lidocaine, in a heated topical patch (Synera) or cream (Pliaglis) leverages the properties of both agents to enhance dermal penetration and provide effective local anesthesia for procedures like IV cannulation or minor dermatological surgeries.[10] Another approach involves combining Tetracaine with a vasoconstrictor. The nasal spray Kovanaze, which pairs Tetracaine with oxymetazoline, provides topical anesthesia for restorative dental procedures. The oxymetazoline constricts local blood vessels, which serves to prolong the anesthetic effect of Tetracaine at the site of action and reduce its systemic absorption, thereby lowering the risk of toxicity.[10] This strategy mirrors the long-standing practice of adding epinephrine to Tetracaine for spinal anesthesia. These developments suggest that the future of Tetracaine may lie less in its use as a standalone agent and more as a high-potency component in intelligently designed combination products.

6.2.1 The Evolving Debate: Topical Tetracaine for Corneal Abrasions

One of the most active and contentious areas of recent Tetracaine research revolves around its outpatient use for the pain of corneal abrasions.

• The Traditional Dogma: For decades, established medical teaching has strongly discouraged the practice of sending patients home with topical anesthetics.[42] This dogma is based on a well-founded fear of anesthetic abuse keratopathy, supported by numerous case reports of severe corneal damage and animal studies demonstrating the toxicity of prolonged anesthetic exposure to the cornea.[42]
• Challenging the Dogma with Evidence: In recent years, this long-held view has been challenged by a series of prospective, randomized, double-blind clinical trials designed to rigorously evaluate the safety and efficacy of short-term, controlled use of topical Tetracaine for uncomplicated corneal abrasions.[49] This represents a classic example of evidence-based medicine questioning established practice. The core of the debate lies in distinguishing between the known dangers of uncontrolled patient abuse and the potential benefits of controlled therapeutic use.
• Key Findings and Contradictions:
• Safety: Several well-designed studies, including a trial of 116 patients, found that a short course of topical Tetracaine (e.g., 1% drops used as needed for 24 hours) was safe. These studies reported no significant difference in the rate of corneal healing at 48 hours and no increase in complications compared to a saline placebo.[50]
• Efficacy: The evidence for pain relief, however, is mixed and less conclusive. One major trial found no statistically significant difference in patient-reported visual analogue scale (VAS) pain scores over time between the Tetracaine and placebo groups. However, in that same study, patients in the Tetracaine group subjectively rated the treatment as significantly more effective and consumed far fewer oral opioid tablets for breakthrough pain (a median of 1 tablet vs. 7).[53] Other studies have reported a significant decrease in pain with topical anesthetic use.[50] In contrast, a comprehensive 2023 Cochrane Database of Systematic Reviews analyzed nine trials and concluded that there was "little or no certainty" about the efficacy of topical anesthetics for reducing pain from corneal abrasions. Furthermore, the Cochrane review noted that in some trials, topical anesthetics were associated with an increased risk of persistent epithelial defects at follow-up.[55]
• Current State of the Debate: The controversy is unresolved. While modern evidence suggests that short-term, judicious use of topical Tetracaine is likely much safer than historical dogma would suggest, its benefit for pain control is not definitively proven, and a risk of delayed healing, though perhaps small, cannot be entirely dismissed. The practice remains a subject of active debate among ophthalmologists and emergency physicians.

---

Table 6.1: Summary of Key Clinical Trials Involving Tetracaine

ClinicalTrials.gov ID	Study Objective	Intervention	Comparison	Key Findings	Source(s)
NCT04187417 (Waldman et al.)	Evaluate safety and efficacy of short-term topical tetracaine for corneal abrasion pain.	Tetracaine 1% drops (undiluted, preservative-free) up to every 30 min for 24 hrs.	Saline placebo drops.	Safety: No complications attributed to tetracaine; no difference in healing at 48 hrs. Efficacy: No difference in VAS pain scores, but patients rated tetracaine as significantly more effective and used fewer opioids.	49
NCT02483897	Assess effect of tetracaine on pain and healing in uncomplicated acute corneal injuries.	Tetracaine 0.5% drops hourly as needed for pain.	Saline placebo drops.	Study designed to address limitations of prior studies by assessing pain at earlier time points. (Status: Recruiting)	50
NCT01383200	Compare anesthetic effect and comfort of tetracaine vs. lidocaine gel for LASIK surgery.	Tetracaine 0.5% drops.	Lidocaine 2% gel.	Study was terminated. Results showed no significant difference in pain scores between groups, but patient preference was higher for lidocaine gel.	48
NCT00484393	Pilot study to determine if tetracaine gel reduces pain from intramuscular palivizumab injection in infants.	Tetracaine 4% gel (Ametop®) applied for 30-45 min.	Placebo gel.	Completed pilot study to assess feasibility and detect a pain difference using the FLACC scale.	51
NCT01055444	Explore usefulness of a heated lidocaine/tetracaine patch for shoulder impingement syndrome pain.	Heated Lidocaine 70 mg / Tetracaine 70 mg patch (Synera®) applied for 2-4 hrs, twice daily for 14 days.	Open-label pilot study (no control group).	Completed pilot study to evaluate efficacy variables for assessing pain responses in this population.	37

---

Section 7: Comparative Analysis and Expert Perspective

To fully appreciate the clinical role of Tetracaine, it must be viewed in the context of other commonly used local anesthetics. Its unique combination of properties defines its specific clinical niche. This section provides a comparative analysis and a concluding expert perspective on its place in the modern anesthetic armamentarium.

7.1 Comparative Analysis with Other Local Anesthetics

The choice of a local anesthetic is a clinical decision based on the required potency, onset, and duration of action, balanced against the risks of toxicity and allergy. Tetracaine is best understood by comparing it to procaine (another ester) and lidocaine and bupivacaine (two common amides).

• Chemical Class and Metabolism: This is the most fundamental distinction.
• Esters (Tetracaine, Procaine): These agents are metabolized by plasma cholinesterases. This pathway is relatively rapid but can be impaired in patients with enzyme deficiencies. Their metabolism produces PABA, which is the primary cause of the higher allergic potential associated with this class.[7]
• Amides (Lidocaine, Bupivacaine): These agents undergo more complex metabolism in the liver by microsomal enzymes. This process is slower but more reliable. True allergic reactions to amides are exceedingly rare.[7]
• Potency: Potency is strongly correlated with lipid solubility.
• High Potency: Tetracaine and Bupivacaine.
• Intermediate Potency: Lidocaine.
• Low Potency: Procaine. Tetracaine is about 10 times more potent than procaine, and bupivacaine is about 4 times more potent than mepivacaine (which is similar to lidocaine).24
• Onset of Action:
• Rapid Onset: Lidocaine.
• Slow Onset: Tetracaine, Bupivacaine, and Procaine all have a longer latency period (typically 5-10 minutes or more for nerve blocks) compared to lidocaine.[27]
• Duration of Action: Duration is influenced by protein binding and rate of metabolism.
• Long Duration: Tetracaine and Bupivacaine (2-3+ hours).
• Intermediate Duration: Lidocaine.
• Short Duration: Procaine (<90 minutes).[24]
• Systemic Toxicity: The risk of systemic toxicity is generally proportional to potency.
• Bupivacaine is notoriously cardiotoxic, with a higher propensity to cause severe ventricular arrhythmias compared to other agents.
• Tetracaine is the most systemically toxic of the ester anesthetics due to its slow rate of hydrolysis, which allows plasma levels to build.[24]
• Lidocaine has a moderate toxicity profile.
• Procaine has the lowest toxicity risk due to its rapid hydrolysis.

---

Table 7.1: Comparative Profile of Common Local Anesthetics

Agent	Chemical Class	Relative Potency	Onset of Action	Duration of Action	Metabolism Pathway	Key Toxicity / Allergy Concerns
Tetracaine	Ester	High (10x Procaine)	Slow	Long (2-3+ hrs)	Plasma Cholesterase	Highest toxicity of esters (slow hydrolysis); PABA-mediated allergy risk.
Procaine	Ester	Low (Reference=1)	Slow	Short (<90 min)	Plasma Cholesterase	Lowest toxicity; PABA-mediated allergy risk.
Lidocaine	Amide	Intermediate	Rapid	Intermediate (1-2 hrs)	Hepatic (Liver)	Moderate CNS/CVS toxicity; allergy is extremely rare.
Bupivacaine	Amide	High (4x Lidocaine)	Slow	Long (2-3+ hrs)	Hepatic (Liver)	High toxicity, particularly cardiotoxicity; allergy is extremely rare.

Data synthesized from sources [7], and.[24]

---

7.2 Clinical Perspective: Balancing Potency, Duration, and Risk

The selection of a local anesthetic is a nuanced clinical judgment. Tetracaine occupies a specific and important niche within this decision-making framework. As a potent, long-acting ester anesthetic, it serves as a valuable alternative to long-acting amides like bupivacaine, particularly for spinal anesthesia. It may be chosen for patients with a confirmed (though rare) allergy to amide anesthetics.

However, its primary modern role has shifted towards topical applications. Its high potency makes it exceptionally effective for producing surface anesthesia on the cornea and skin, where the total dose administered is small, minimizing the risk of systemic toxicity. The development of combination products like Synera and Kovanaze further leverages this high topical potency while incorporating other agents (lidocaine, oxymetazoline) to enhance its performance and safety profile. The ongoing debate over its use for corneal abrasions underscores the central clinical challenge of Tetracaine: how to harness its profound anesthetic power while rigorously managing the risks inherent in its pharmacology.

7.3 Concluding Remarks and Future Directions

Tetracaine is a venerable and highly effective local anesthetic whose nearly century-long history in medicine is a testament to its clinical efficacy. Its pharmacological profile is defined by a critical and inseparable trade-off: its high potency and long duration of action, which are direct consequences of its high lipid solubility and slow metabolic hydrolysis, are the very same properties that confer a higher risk of systemic toxicity compared to other ester anesthetics and a different risk profile from the amides.

The future of Tetracaine is likely to advance along two primary trajectories. First is the pursuit of definitive clinical evidence to resolve the ongoing controversy surrounding its short-term topical use for corneal abrasions. Larger, well-designed randomized controlled trials with long-term ophthalmologic follow-up are needed to provide clear guidance for clinicians. Second is the continued innovation in formulation science. The development of synergistic combination products and novel delivery systems, such as liposomal formulations designed to prolong local action and reduce systemic exposure [24], represents a promising path to harness Tetracaine's potency while improving its safety margin. Concurrently, its enduring role as a specific pharmacological probe for studying intracellular calcium dynamics ensures its continued relevance in basic science research, where it will help to uncover fundamental mechanisms of cellular physiology.

Works cited

1. Tetracaine - Wikipedia, accessed August 7, 2025, https://en.wikipedia.org/wiki/Tetracaine
2. Tetracaine | C15H24N2O2 | CID 5411 - PubChem, accessed August 7, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Tetracaine
3. Tetracaine Cream: Uses & Side Effects - Cleveland Clinic, accessed August 7, 2025, https://my.clevelandclinic.org/health/drugs/19713-tetracaine-skin-gel-solution-or-cream
4. Pontocaine - Wood Library-Museum of Anesthesiology, accessed August 7, 2025, https://www.woodlibrarymuseum.org/museum/pontocaine/
5. Tetracaine | CAS#94-24-6 | local anesthetic - MedKoo Biosciences, accessed August 7, 2025, https://www.medkoo.com/products/16293
6. Tetracaine - StatPearls - NCBI Bookshelf, accessed August 7, 2025, https://www.ncbi.nlm.nih.gov/books/NBK535437/
7. Which of the following local anesthetics is an aminoester: tetracaine, lidocaine, bupivacaine, mepivacaine, or etidocaine? - Dr.Oracle AI, accessed August 7, 2025, https://www.droracle.ai/articles/113161/which-of-the-following-is-an-aminoester-a-tetracaine-b-lidocaine-c-bupivacaine-d-mepivacaine-e-etidocaine
8. Tetracaine: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 7, 2025, https://go.drugbank.com/drugs/DB09085
9. 202123 Tetracaine DD Clinical PREA - FDA, accessed August 7, 2025, https://www.fda.gov/files/drugs/published/202123-Tetracaine-DD-Clinical-PREA.pdf
10. Tetracaine - brand name list from Drugs.com, accessed August 7, 2025, https://www.drugs.com/ingredient/tetracaine.html
11. Tetracaine Hydrochloride Ophthalmic Solution 0.5% - FDA, accessed August 7, 2025, https://www.fda.gov/files/drugs/published/202123-Tetracaine-Clinpharm-PREA.pdf
12. 202123 Tetracaine Clinical PREA - FDA, accessed August 7, 2025, https://www.fda.gov/files/drugs/published/202123-Tetracaine-Clinical-PREA.pdf
13. Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5%, accessed August 7, 2025, https://pi.bausch.com/globalassets/pdf/PackageInserts/Pharma/Rx-Generics/Tetracaine_Hydrochloride_Ophth_Sol_0.5_percent.pdf
14. 208135Orig1s000 - accessdata.fda.gov, accessed August 7, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208135Orig1s000PharmR.pdf
15. Tetracaine - CAS-Number 94-24-6 - Order from Chemodex, accessed August 7, 2025, https://www.chemodex.com/products/tetracaine/
16. SAFETY DATA SHEET - Fisher Scientific, accessed August 7, 2025, https://www.fishersci.com/store/msds?partNumber=AC460820250&countryCode=US&language=en
17. TETRACAINE 1% - DailyMed, accessed August 7, 2025, https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b29124f7-c238-4961-b810-f4e7fabe4bb1
18. Tetracaine Monograph for Professionals - Drugs.com, accessed August 7, 2025, https://www.drugs.com/monograph/tetracaine.html
19. Safety Data Sheet - Cayman Chemical, accessed August 7, 2025, https://cdn.caymanchem.com/cdn/msds/30059m.pdf
20. Tetracaine | CAS 94-24-6 | SCBT - Santa Cruz Biotechnology, accessed August 7, 2025, https://www.scbt.com/p/tetracaine-94-24-6
21. Embutramide / Mebezonium / Tetracaine For- mulation - Merck.com, accessed August 7, 2025, https://www.merck.com/docs/product/safety-data-sheets/ah-sds/Embutramide%20and%20Mebezonium%20and%20Tetracaine%20Formulation_AH_IE_6N.pdf
22. www.accessdata.fda.gov, accessed August 7, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208135s000lbl.pdf
23. What is the mechanism of Tetracaine? - Patsnap Synapse, accessed August 7, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-tetracaine
24. Local Anesthetics | Basicmedical Key, accessed August 7, 2025, https://basicmedicalkey.com/local-anesthetics-5/
25. Local Anesthetics | Anesthesia Key, accessed August 7, 2025, https://aneskey.com/local-anesthetics-16/
26. Tetracaine: Uses, Side Effects, Alternatives & More - GoodRx, accessed August 7, 2025, https://www.goodrx.com/tetracaine/what-is
27. Local Anesthetics Used for Spinal Anesthesia, accessed August 7, 2025, http://ifna.site/ifna/e107_files/downloads/lectures/H9LocalAne.pdf
28. www.drugs.com, accessed August 7, 2025, https://www.drugs.com/monograph/tetracaine.html#:~:text=Tetracaine%20Pharmacokinetics&text=Duration%20of%20action%20during%20spinal,excreted%20mainly%20by%20the%20kidneys.
29. Data Sheet Minims Tetracaine Hydrochloride - Medsafe, accessed August 7, 2025, https://www.medsafe.govt.nz/profs/datasheet/m/Minims-Tetracainehydrochlorideeyedrops.pdf
30. www.ncbi.nlm.nih.gov, accessed August 7, 2025, https://www.ncbi.nlm.nih.gov/books/NBK535437/#:~:text=Tetracaine%20is%20an%20amino%2Dester,anesthesia%20is%20also%20another%20indication.
31. Tetracaine (ophthalmic route) - Side effects & uses - Mayo Clinic, accessed August 7, 2025, https://www.mayoclinic.org/drugs-supplements/tetracaine-ophthalmic-route/description/drg-20074790
32. Tetracaine eye solution - Cleveland Clinic, accessed August 7, 2025, https://my.clevelandclinic.org/health/drugs/19273-tetracaine-eye-solution
33. Tetcaine, tetracaine ophthalmic (tetracaine) dosing, indications, interactions, adverse effects, and more. - Medscape Reference, accessed August 7, 2025, https://reference.medscape.com/drug/pontocaine-tetcaine-tetracaine-343373
34. Label: TETRACAINE HYDROCHLORIDE solution - DailyMed, accessed August 7, 2025, https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5c7b1de4-9f55-1d0e-ef6d-b0ba2cbaba79
35. Tetracaine topical Uses, Side Effects & Warnings - Drugs.com, accessed August 7, 2025, https://www.drugs.com/mtm/tetracaine-topical.html
36. Lidocaine and tetracaine (topical application route) - Side effects & uses - Mayo Clinic, accessed August 7, 2025, https://www.mayoclinic.org/drugs-supplements/lidocaine-and-tetracaine-topical-application-route/description/drg-20072742
37. Study Evaluating Heated Lidocaine/Tetracaine Topical Patch in Treatment of Patients With Shoulder Impingement Syndrome | ClinicalTrials.gov, accessed August 7, 2025, https://www.clinicaltrials.gov/study/NCT01055444
38. Tetracaine (Topical: Pediatric Medication | Memorial Sloan Kettering Cancer Center, accessed August 7, 2025, https://www.mskcc.org/cancer-care/patient-education/medications/pediatric/tetracaine-topical
39. www.caymanchem.com, accessed August 7, 2025, https://www.caymanchem.com/product/30059/tetracaine#:~:text=Product%20Description,standard%20categorized%20as%20an%20anesthetic.&text=Tetracaine%20has%20been%20found%20as,as%20male%20sexual%20function%20enhancers.&text=This%20product%20is%20intended%20for%20research%20and%20forensic%20applications.
40. Synera (lidocaine and tetracaine) FDA Approval History - Drugs.com, accessed August 7, 2025, https://www.drugs.com/history/synera.html
41. Kovanaze FDA Approval History - Drugs.com, accessed August 7, 2025, https://www.drugs.com/history/kovanaze.html
42. Topical Anesthetic Abuse Keratopathy - EyeWiki, accessed August 7, 2025, https://eyewiki.org/Topical_Anesthetic_Abuse_Keratopathy
43. Tetracaine (Ophthalmic | Memorial Sloan Kettering Cancer Center, accessed August 7, 2025, https://www.mskcc.org/cancer-care/patient-education/medications/adult/tetracaine-ophthalmic?mode=large&msk_tools_print=pdf
44. Local anesthetic toxicity: acute and chronic management - PMC - PubMed Central, accessed August 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5667269/
45. Tetracaine - Santa Cruz Biotechnology, accessed August 7, 2025, https://datasheets.scbt.com/sc-255645.pdf
46. Tetracaine hydrochloride - Safety Data Sheet - ChemicalBook, accessed August 7, 2025, https://www.chemicalbook.com/msds/tetracaine-hydrochloride.pdf
47. tetracaine topical, accessed August 7, 2025, https://www.myactivehealth.com/hwcontent/content/multum/d03982a1.html
48. Tetracaine Terminated Phase 4 Trials for Pain Supportive Care | DrugBank Online, accessed August 7, 2025, https://go.drugbank.com/drugs/DB09085/clinical_trials?conditions=DBCOND0012160&phase=4&purpose=supportive_care&status=terminated
49. Study Details | Short Term Topical Tetracaine is Safe and Highly ..., accessed August 7, 2025, https://clinicaltrials.gov/study/NCT04187417?term=AREA%5BInterventionSearch%5D(amethocaine)&rank=8
50. Effect of Tetracaine on Pain Management and Corneal Healing in Patients With Acute Corneal Abrasion | ClinicalTrials.gov, accessed August 7, 2025, https://clinicaltrials.gov/study/NCT02483897
51. Tetracaine Compared to Placebo for Reducing Pain With Palivizumab - A Pilot Study, accessed August 7, 2025, https://clinicaltrials.gov/study/NCT00484393
52. Search for: Other terms: LIDOCAINE AND TETRACAINE | Card Results | ClinicalTrials.gov, accessed August 7, 2025, https://www.clinicaltrials.gov/ct2/results?submit=Search&term=LIDOCAINE+AND+TETRACAINE
53. Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial - PubMed, accessed August 7, 2025, https://pubmed.ncbi.nlm.nih.gov/24730399/
54. Topical Tetracaine Used for 24 Hours Is Safe and Rated Highly Effective by Patients for the Treatment of Pain Caused by Corneal Abrasions - Emergency Medicine, accessed August 7, 2025, https://emergencymedicine.wustl.edu/app/uploads/2021/02/PGY-1-AEM-24-hours-of-tetracaine.pdf
55. Topical Anesthetics: The Latest on Use for Corneal Abrasions, accessed August 7, 2025, https://www.aao.org/eyenet/article/topical-anesthetics
56. Periodic Classification of Local Anaesthetics (Procaine Analogues) - MDPI, accessed August 7, 2025, https://www.mdpi.com/1422-0067/7/1/12